| Gender Preference | None |
| Age Group | 0 - 80 years |
| Research Start Date | November 1, 2012 |
| Research End Date | September 13, 2013 |
| Principal Investigator | Frances Johnson, MD |
| Description | A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects With Heart Failure. The purpose of this trial is to assess whether MYDICAR can reduce the frequency and/or delay heart failure related hospitalizations in persons with advanced heart failure when added to their maximal and optimized therapy.
Please refer to www.clinicaltrials.gov identifier NCT01643330
for more information. |
| Contact Info | A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure (CUPID-2b)
Cardiomyopathy Treatment Program
Cynthia Larew, RN BSN
phone: 319-356-1028
fax: 319-356-7087
email: cynthia-larew@uiowa.edu |
| Keywords | span itemProp='description'>cardiomyopathy ; CHF ; congestive heart failure ; Enter keyword ; gene therapy ; heart ; heart disease ; heart failure ; left ventricular failure ; undefined ; |